Analyst Ratings For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Today, Raymond James initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a Outperform.
There are 15 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Buy with a consensus target price of $114.5725 per share, a potential 24.02% upside.
Some recent analyst ratings include
- 4/9/2019-BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has coverage initiated with a Outperform rating
- 4/2/2019-BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) had its Buy rating reiterated by Cantor Fitzgerald with a $131.00 price target
- 2/24/2019-BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) had its Hold rating reiterated by Barclays with a $95.00 price target
- On 4/1/2019 Daniel K Spiegelman, CFO, sold 13,473 with an average share price of $89.00 per share and the total transaction amounting to $1,199,097.00.
- On 3/27/2019 Daniel K Spiegelman, CFO, sold 100 with an average share price of $90.00 per share and the total transaction amounting to $9,000.00.
- On 3/27/2019 V Bryan Lawlis, Director, sold 2,150 with an average share price of $89.76 per share and the total transaction amounting to $192,984.00.
- On 3/25/2019 George Eric Davis, EVP, sold 3,363 with an average share price of $87.86 per share and the total transaction amounting to $295,473.18.
- On 3/25/2019 Henry J Fuchs, Insider, sold 5,932 with an average share price of $87.86 per share and the total transaction amounting to $521,185.52.
- On 3/25/2019 Jean Jacques Bienaime, CEO, sold 4,000 with an average share price of $87.86 per share and the total transaction amounting to $351,440.00.
- On 3/21/2019 Jeffrey Robert Ajer, EVP, sold 4,519 with an average share price of $89.98 per share and the total transaction amounting to $406,619.62.
About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Recent Trading Activity for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Shares of BioMarin Pharmaceutical Inc. closed the previous trading session at 92,38 −1,52 1,62 % with 93.76 shares trading hands.